Journalism Grants

Funding For:

A Turning Point in the Addiction Crisis

Prescription Drugs / Substance Use


Recipient:

STAT

Grant Period:

Jan 01, 2022 - Dec 31, 2022

AMOUNT:

$25,000.00

Summary of the Project:

Through a series of multimedia articles, this project will discuss the future of the addiction crisis and grapple with the looming — and enormous — challenges that public health officials, providers and patients are facing as the epidemic enters a new stage.

About the Grantee:

With an award-winning newsroom, STAT is a media company focused on finding and telling compelling stories about health, medicine and scientific discovery. STAT produces daily news, investigative articles and narrative projects in addition to multimedia features.


Related Grantee Work

March 11, 2022

With overdoses at record highs, a veterinary tranquilizer spreading through the U.S. drug supply poses new threats

With overdoses at record highs, a veterinary tranquilizer spreading through the U.S. drug supply is posing new threats.

Learn More

Author: Andrew Joseph

April 12, 2022

Driven by fentanyl, rates of fatal teen overdoses doubled in 2020

What teens may think is an opioid painkiller or Xanax diverted from the legal supply is now more likely to be a counterfeit tablet containing fentanyl or similar synthetic opioids.

Learn More

Author: Andrew Joseph

June 22, 2022

To protect people with addiction from discrimination, the Justice Dept. turns to a long-overlooked tool: the ADA

“This kind of discrimination is overt,” Gregory Dorchak, an assistant U.S. attorney in Massachusetts who has led many of these investigations, said on a recent webinar.

Learn More

Author: Andrew Joseph

July 25, 2022

Two deadly days in St. Louis: An overdose cluster kills 8 Black people — and shows the new shape of the addiction crisis

"Everyone should be running around with Narcan in their cars. There should be much more urgency.”

Learn More

Author: Andrew Joseph

December 22, 2022

Under new rules, methadone clinics can offer more take-home doses. Will they?

Learn More

Author: Andrew Joseph